Zydus receives tentative approval from the USFDA for Deferasirox Tablets for Oral Suspension

Zydus receives tentative approval from the USFDA for Deferasirox Tablets for Oral Suspension Ahmedabad, 07 July, 2018 Zydus Cadila has received the tentative approval from the USFDA to market Deferasirox Tablets for Oral Suspension (Exjade Tablets) in the strengths of 125 mg, 250 mg and 500 mg. It is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to trea t high levels of iron in people with a certain blood disorder who do not require blood transfusions (non -transfusion-dependent thalassemia). It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The estimated sale for Deferasirox Tablets is $ 150.3 million (Source: IMS Health, IMS National Sales Perspective Audit, MAT May 2018, extracted June 2018.) In line with this, the group now has 202 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 22,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗